April 13, 2026 |
Discover how teams from across Inizio provided a range of integrated services to give a client’s product the best chance of launch success.

Discover how teams from across Inizio provided a range of integrated services to give a client’s product the best chance of launch success – including market analysis, sales teams, MSLs, training, launch meeting support, congress experiences, and product value demonstration.  Â
Our client is a US biotechnology company that specializes in developing therapies for complex and chronic conditions. For many years, the firm has been working on what’s become the first new FDA-approved therapy of its kind in almost two decades. Â
Our client’s landmark product is an easy-to-use therapy that allows for rapid absorption and targets various receptors. In clinical trials, the treatment was shown to significantly reduce pain.Â
Primarily, the client needed a commercialization partner to rapidly set up a large, flexible nationwide sales team ready for the product launch in October 2025.Â
Read the full case study here.
This content was provided by Inizio
Latest Content from Inizio
Watch our short video to see how we have grown. Please note the video comes with some fun, themed music. https://www.researchpartnership.com/news/2017/06/research-partnership-is-celebrating-20-years-in-bus…
This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in…
Research Partnership is delighted to welcome Anne Cunningham and Morten Andersen and announce that Sue Rees has joined our specialist Emerging Markets team.
We are delighted to be presenting a paper and exhibiting at the Pharmaceutical Market Research Conference 13-14 June in Bay Area close to our new office in San Francisco.Representing Research…
Visit us on stand number 14
We are delighted to announce that Research Partnership’s Director Richard Head has been nominated for The EphMRA President’s Award for Contribution to Pharmaceutical Market Research.According to EphMRA, Richard has been…
Living with Non-alcoholic Steatohepatitis (NASH) is a study conducted amongst 100 adults with NASH in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase…
Join us at EULAR Congress 2017 in Madrid, 14-17 June
Pegasus, an Ashfield company, part of UDG Healthcare plc, has unveiled a new brand identity signaling its successful integration with the global business, a year on from acquisition. Conceived by…
